Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Halozyme Q1 Loss Widens - Quick Facts

5/7/2012 6:13 PM ET

Halozyme Therapeutics, Inc. (HALO: Quote) Monday reported a first-quarter loss of $15.1 million or $0.14 per share, which widened from $9.6 million or $0.10 per share in the year-ago period.

On average, eight analysts polled by Thomson Reuters expected the company to report a loss of $0.11 per share for the first quarter. Analysts' estimates typically exclude special items.

First-quarter revenues declined to $7.4 million from $7.5 million last year. Analysts expected revenues of $7.31 million for the quarter.

Click here to receive FREE breaking news email alerts for Halozyme Therapeutics, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks continue to show a lack of direction in mid-day trading on Thursday, extending the lackluster performance seen earlier in the session. The major averages have spent the day bouncing back and forth across the unchanged line. After speaking with President Barack Obama by phone about stalled immigration reform legislation on Wednesday, House Majority Leader Eric Cantor, R-Virg., claimed the president still does not understand how to work with the Republican-controlled House. Growth in Philadelphia-area manufacturing activity has accelerated by much more than anticipated in the month of April, according to the results of the Federal Reserve Bank of Philadelphia's Business Outlook Survey released on Thursday. The Philly Fed said its diffusion index of current activity climbed to 16.6 in April from 9.0 in March, with a positive reading indicating growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.